SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 15, 2009
|
MERIDIAN
BIOSCIENCE, INC.
|
|
(Exact
name of registrant as specified in its
charter)
|
|
Ohio
|
0-14902
|
31-0888197
|
||||||
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No. )
|
||||||
|
3471
River Hills Drive, Cincinnati, Ohio
|
45244
|
|||||||
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|||||||
Registrant’s
telephone number, including area code (513)
271-3700
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-2)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other Events.
Meridian
Bioscience, Inc. (the “Company”) has been advised that John A. Kraeutler, Chief
Executive Officer of the Company, has entered into a stock trading plan designed
to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934, as
amended. Under Rule 10b5-1(c), directors and officers may adopt a
prearranged plan or contract for the sale of Company securities under specified
conditions and at specified times.
Mr.
Kraeutler’s plan allows for the sale of up to 100,000 shares of the Company’s
common stock and provides for sales of specified share amounts at specified
market prices, subject to specified limitations. This plan was
established during the Company’s current trading window.
Except as
may be required by law, the Company does not undertake to report stock trading
plans by other Company officers or directors, nor to report modifications,
transactions or other activities under Mr. Kraeutler’s plan or the plan of any
other officer or director.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MERIDIAN
BIOSCIENCE, INC.
|
|||
|
Date:
December 15, 2009
|
By:
|
/s/Melissa Lueke | |
| Melissa Lueke | |||
|
Vice
President and Chief Financial Officer
(Principal Accounting Officer)
|
|||